-
Product Insights
Familial Amyloid Cardiomyopathy - Drugs In Development, 2024
Empower your strategies with our Familial Amyloid Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid cardiomyopathy (ATTR-CM), results from the aggregation and deposition of mutant and wild-type transthyretin (TTR) protein in the heart. TTR is usually circulated as a homo-tetramer; however, in FAC patients, TTR dissociates and misassembles into amyloid fibrils that are insoluble and resistant to degradation. Due to this resistance to degradation, when amyloid fibrils accumulate in...
-
Product Insights
Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Drugs In Development, 2024
Empower your strategies with our Familial Chylomicronemia (Type I Hyperlipoproteinemia) – Drugs In Development, 2024 report and make more profitable business decisions. Familial chylomicronemia syndrome (hyperlipoproteinemia type 1) is an inherited condition that disrupts the breakdown of fats in the body, causing high levels of fat to build up in the blood. It is characterized by pancreatitis, abdominal pain, enlargement of the liver and spleen (hepatosplenomegaly), and small yellow skin lesions called eruptive xanthomas. Familial chylomicronemia syndrome is caused by genetic...
-
Product Insights
Heredofamilial Amyloidosis - Drugs In Development, 2024
Empower your strategies with our Heredofamilial Amyloidosis – Drugs In Development, 2024 report and make more profitable business decisions. Heredofamilial Amyloidosis refers to a group of inherited disorders characterized by the deposition of abnormal amyloid proteins in tissues and organs throughout the body. Amyloidosis occurs when certain proteins misfold and aggregate, forming insoluble fibrils that can accumulate in organs and tissues, disrupting their normal function. The term "heredofamilial" indicates that these conditions have a genetic basis and can be inherited to...
-
Product Insights
Propionic Acidemia - Drugs In Development, 2024
Empower your strategies with our Propionic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions. The spectrum of propionic acidemia (PA) ranges from neonatal-onset to late-onset disease. Neonatal-onset PA is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis, this is followed by progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death. Individuals with...
-
Product Insights
Familial Amyloid Neuropathies - Drugs In Development, 2024
Empower your strategies with our Familial Amyloid Neuropathies – Drugs In Development, 2024 report and make more profitable business decisions. Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness,...
-
Product Insights
Lipodystrophy (Lipoatrophy) - Drugs In Development, 2024
Empower your strategies with our Lipodystrophy (Lipoatrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Lipodystrophy syndromes comprise a heterogeneous group of disorders characterized by either generalized or partial lack of adipose tissue depending on the type of lipodystrophy. Lipodystrophy has been classified as congenital or acquired. Lipodystrophy syndromes usually manifest with several metabolic abnormalities associated with severe insulin resistance that include diabetes mellitus, hypertriglyceridemia, and hepatic steatosis, which can progress to steatohepatitis. The Lipodystrophy (Lipoatrophy) drugs...
-
Product Insights
Cushing's Syndrome - Drugs In Development, 2024
Empower your strategies with our Cushing's Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress. This may be caused by a variety of factors like long-term use of corticosteroid medications, tumors in the pituitary gland or adrenal adenomas. The...
-
Product Insights
Hypercholesterolemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Hypercholesterolemia Clinical Trial Report Overview A total of 2407 hypercholesterolemia clinical trials were conducted as of May 2024. The hypercholesterolemia clinical trial report provides a comprehensive understanding of the hypercholesterolemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · Europe · Asia-Pacific · ...
-
Sector Analysis
Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and Drug Forecast to 2033
Reasons to buy the ‘GLP-1R Agonists in Type 2 Diabetes and Obesity’ market report: The report provides an overview of GLP-1R agonists, type 2 diabetes, and obesity, including epidemiology, symptoms, diagnosis, and disease management. The report includes annualized GLP-1R agonists therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. The report covers key topics including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the...
-
Sector Analysis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period. GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion) Buy the Full Report to Know More about the GLP-1R Agonists in the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.